Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Cytosorbents Corp | v329137_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 21, 2012
| CYTOSORBENTS CORPORATION |
| (Exact name of registrant as specified in its charter) |
| Nevada | 000-51038 | 98-0373793 |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
|
7 Deer Park Drive, Suite K Monmouth Junction, New Jersey (Address of principal executive offices) |
08852 (Zip Code) |
Registrant’s telephone number, including area code: (732) 329-8885
| N/A |
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.02 | Results of Operations and Financial Condition. |
On November 21, 2012, CytoSorbents Corporation issued a press release entitled “CytoSorbents Updates Corporate Progress and Third Quarter 2012 Financial Results,” a copy of which is furnished with this Current Report on Form 8-K as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit Number | Description of Exhibit | |
| 99.1 | Press release dated November 21, 2012 , “CytoSorbents Updates Corporate Progress and Third Quarter 2012 Financial Results.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CytoSorbents Corporation | ||
| Date: November 21, 2012 | By: | /s/ Dr. Phillip P. Chan |
| Name: Dr. Phillip P. Chan | ||
| Title: President and CEO |